Resistance to Immunotherapeutic Antibodies in Cancer (eBook)

Strategies to Overcome Resistance

Benjamin Bonavida (Herausgeber)

eBook Download: PDF
2013 | 2013
XIII, 202 Seiten
Springer New York (Verlag)
978-1-4614-7654-2 (ISBN)

Lese- und Medienproben

Resistance to Immunotherapeutic Antibodies in Cancer -
Systemvoraussetzungen
149,79 inkl. MwSt
  • Download sofort lieferbar
  • Zahlungsarten anzeigen
????The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can bind only to cancer cell-specific antigens and induce an immunological response against the target cancer cell. The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.

Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. In his career, he's published over 450 papers and reviews, and he's also edited two books with Springer in the past. For more information, please see the CV attached herewith.
????The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can bind only to cancer cell-specific antigens and induce an immunological response against the target cancer cell. The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.

Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. In his career, he's published over 450 papers and reviews, and he's also edited two books with Springer in the past. For more information, please see the CV attached herewith.

​Part I. Immunotherapy with monoclonal antibodies (mAbs) against various cancers
1.Introduction and generation of chimeric and humanized mAbs
2. mAbs targeted against cancer cells and antibodies targeted against the tumor microenvironment
3. Antibodies directed against different major cancers: Effects when used alone or in combination with drugs
4. Mechanisms of antibodies-mediated responses, in vitro and in vivo
Part II. Development of resistance to mAbs
5. Molecular Pathways
6. Molecular Signatures
7. Identification of resistance targets for intervention
Part III. Agents that can sensitize resistant tumor cells to mAbs
8. Various chemicals that can sensitize resitant tumor cells
9. Other mAbs
10. Proteasome inhibitors
Part IV. Novel mAbs to overcome resistance
11. Divalent mAbs
12. Antibodies coupled to chemical inhibitors
13. Antibodies coupled to cytokines 14. Nanoparticles with mAbs ​

Erscheint lt. Verlag 4.8.2013
Reihe/Serie Resistance to Targeted Anti-Cancer Therapeutics
Resistance to Targeted Anti-Cancer Therapeutics
Zusatzinfo XIII, 202 p.
Verlagsort New York
Sprache englisch
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Onkologie
Studium Querschnittsbereiche Infektiologie / Immunologie
Naturwissenschaften Biologie
Technik
Schlagworte antibodies • antibody-drug conjugates • cancer drug resistance • MABS • monoclonal antibody • Rituximab
ISBN-10 1-4614-7654-2 / 1461476542
ISBN-13 978-1-4614-7654-2 / 9781461476542
Haben Sie eine Frage zum Produkt?
PDFPDF (Wasserzeichen)
Größe: 4,5 MB

DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasser­zeichen und ist damit für Sie persona­lisiert. Bei einer missbräuch­lichen Weiter­gabe des eBooks an Dritte ist eine Rück­ver­folgung an die Quelle möglich.

Dateiformat: PDF (Portable Document Format)
Mit einem festen Seiten­layout eignet sich die PDF besonders für Fach­bücher mit Spalten, Tabellen und Abbild­ungen. Eine PDF kann auf fast allen Geräten ange­zeigt werden, ist aber für kleine Displays (Smart­phone, eReader) nur einge­schränkt geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Mehr entdecken
aus dem Bereich
Antibiotika, Virostatika, Antimykotika, Antiparasitäre Wirkstoffe

von Hans-Reinhard Brodt; Achim Hörauf; Michael Kresken …

eBook Download (2023)
Thieme (Verlag)
164,99